Publication

Article

Pharmaceutical Technology

Pharmaceutical Technology-03-02-2002
Volume26
Issue 3

Product Development Issues of Powders for Injection

Author(s):

Arvind K. Bansal

The development of a successful powder for injection formulation requires careful study of preformulation parameters, packaging and process parameters, and the elimination of particulate matter.

External Link - article-12518.pdf

Articles in this issue
Outsourcing Outlook
Developing Custom Adhesive Systems for Transdermal Drug Delivery
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part II
PDA Task Force Issues Guidelines to Aid Isolator Users
Recent Advances in Semisolid Dosage Forms for Dermatological Application
Drug Safety Concerns Shape Manufacturing Policy
Production Information Mangement
Functionality Testing of a Multifunctional Directly Compressible Adjuvant Containing Lactose, Polyvinylpyrrolidone, and Croscarmellose Sodium
Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives
Validation Changes to the USP Assay Method for Ibuprofen Tablets
Systematic Troubleshooting for LC/MS/MS
Product Development Issues of Powders for Injection
Oral Low Molecular Weight Heparin Absorption From Solution and Solid Dosage Forms in Rat, Dog, and Monkey Models
Pharmaceutical Reserch and Manufacturers Association Acceptable Analytical Practice for Analytical Method Transfer

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Related Content
Young man having asthma attack or choking suffering from respiration problems | Image Credit: © Feodora - stock.adobe.com
July 18th 2025

UK Anaphylaxis Nasal Spray Approval Helps Reshape Emergency Allergy Treatment

Christopher Cole
Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com
June 24th 2025

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
Drug Solutions Podcast: mRNA Past, Present, and Future
August 17th 2023

Drug Solutions Podcast: mRNA Past, Present, and Future

Chris Spivey
An mRNA conversation about the recent past, current hot topics, and probable future.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
March 25th 2025

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
February 17th 2025

FDA Approves Evrysdi Tablet from Roche for Spinal Muscular Atrophy

Feliza Mirasol
The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.